Evaluate the long-term safety and maintenance of efficacy of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer's type in Veterans at the Ralph H. Johnson VA Medical Center in Charleston, SC.
Inclusion in this study requires successful completion of studies 15-AVP-786-301, 15-AVP-786-302, 17-AVP-786-305 or 12-AVR-131 and a reliable caregiver who is able and willing to comply with all required study procedures.
The purpose of this study is to understand how networks in the brain change over time. Participants will have 2 study visits (about 2 years apart) where they will undergo tests to assess mental function, fill out questionnaires, and undergo a brain MRI. At the first visit only, participants will also undergo a blood draw and a PET scan.
Participants are required to have a Co-Participant accompany them. This individual must be a reliable informant that has contact with the participant at least once per week.
The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer's type.
Subjects are being asked to volunteer for a research study because they have been diagnosed with Alzheimer's disease. Alzheimer's dementia is the most common form of dementia. It is a general term for memory loss and loss of other intellectual abilities that are serious enough to interfere with daily activities.
The purpose of this study is to see if the investigational drug, LY3314814 (study drug) can slow the progression of your Alzheimer's disease. In Part I of the study, subjects will either receive the study drug or placebo. After 78 weeks, all subjects will begin Part II where everyone is on the study drug.
Alzheimer's disease and the isolation it produces imposes a heavy burden on informal caregivers (CG) of Veterans who are persons with dementia (PWD), who carry greater burden than those caring for persons with other chronic diseases. This feasibilty study will test a mobile application (APP) on a mini-iPad designed for caregivers of community-dwelling Veterans who are PWD in comparison with Web-based informational materials. Building on story-telling interventions effective in other chronic diseases, this feasibilty study proposes Story-Call as a newly-developed mobile application that records, archives, and presents 30/60-second videos by caregivers and professionals, who share brief stories about how they have handled common dementia home-care situations, such as "She wants to go home!" A qualitative component will categorize themes from stories and in 2 phases collect: 1) perceptions from follow-up phone interviews with CG participants; and 2) focus groups with Advisory Group and VA stakeholders as a process evaluation of APP appeal, use, impact, and cultural tailoring. The expected outcomes will examine if CGs find that the APP-recorded stories decrease perceived CG burden and increase social support as efficacy, while confirming feasibility in recruitment, acceptability, practicality, increased adaptation to dementia care, and use of community resources for future scaling up and testing.
This is a study of brain aging and Mild Cognitive Impairment (MCI). In this study, we use non-invasive brain MRI techniques and tests of memory and other thinking skills to improve the detection of brain diseases of aging at the very earliest stages. A fasting blood draw will also be performed to help clarify the contribution of blood sugar and cholesterol to brain aging. We are primarily recruiting 80 individuals ages 65-85 who have been diagnosed with Mild Cognitive Impairment (MCI) by their healthcare provider. We are also recruiting individuals ages 65-85 who are cognitively healthy and do not have any significant or unstable medical conditions. This study is sponsored by the NIH and is conducted at MUSC.
If you are interested in this study, please contact us by phone or through: http://bit.ly/MIND-study
This study is designed to examine the effects and safety of citalopram in patients with Alzheimer's disease experiencing agitation or emotional disturbance. This study is 9 weeks long. In order to participate in this study, you must be at least 45 years old, have Alzheimer's disease and experience agitation. Participants cannot have depression. Participants may stay on approved memory medications for Alzheimer's disease.